Bubble or no bubble, this is the best stock for AI exposure: analyst
Anshul Maheshwari, Chief Financial Officer of SI-BONE, Inc. (NASDAQ:SIBN), sold 1,300 shares of common stock for approximately $26,015, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as SI-BONE’s stock trades near its 52-week high of $20.05, having delivered an impressive 55.45% return over the past year. With a current market capitalization of $855.24 million, InvestingPro data shows the stock’s RSI suggests it’s in overbought territory.
The sales occurred in two separate transactions. On November 21, 2025, Maheshwari sold 1,200 shares at a weighted-average price of $20.0133, in multiple transactions ranging from $20.00 to $20.02. Following this, on November 25, 2025, the CFO sold an additional 100 shares at $20.00 per share.
The sales were executed under a pre-arranged 10b5-1 trading plan established on December 13, 2024. Following the transactions, Maheshwari directly owns 203,773 shares of SI-BONE, Inc., which includes 143,116 shares issuable on settlement of restricted stock units. Despite strong revenue growth of 23.27% over the last twelve months, analysts do not anticipate the company will be profitable this year. Discover more insights with InvestingPro, which offers 8 additional ProTips and comprehensive analysis on SI-BONE’s financial health.
In other recent news, SI-BONE Inc. reported its third-quarter 2025 earnings, surpassing expectations for both earnings per share (EPS) and revenue. The company posted an EPS of -$0.11, beating the forecasted -$0.17, and reported revenue of $48.7 million, exceeding the anticipated $46.67 million. This represents a year-over-year revenue growth of approximately 21%. Following these results, SI-BONE’s management has raised its full-year 2025 revenue guidance. Cantor Fitzgerald reiterated its Overweight rating with a $25.00 price target, acknowledging the company’s strong financial performance. Similarly, Needham maintained its Buy rating with a $24.00 price target. These developments indicate positive sentiment from analysts regarding SI-BONE’s recent performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.